Cenicriviroc: Phase IIa started

Tobira began the double-blind, placebo-controlled, U.S. Phase IIa ORION trial to evaluate 150 mg oral cenicriviroc once daily for 24 weeks in about 50 obese patients. Tobira has exclusive, worldwide r...